A 75-Year-Old Male Develops Painful Erythema Around His Nails After Starting Treatment

Poll

A 75-year-old male patient develops painful erythema around his nails 10 weeks after starting cancer treatment. Which medication is most likely responsible?

A 75-year-old male patient develops painful erythema around his nails 10 weeks after starting cancer treatment. According to the image below, which medication is most likely responsible?

Image courtesy of Shivani V. Tripathi, M.D.  and  Milan J. Anadkat, M.D.

What is your diagnosis?

A. Cyclophosphamide
B. Cetuximab
C. Docetaxel
D. Hydroxyurea

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Ronald Bleday, MD, stated that before standardizing a stepwise approach to treating surgical pain, providers might have overtreated patients with opioids.
1 expert is featured in this series.
Related Content
It was noted that in those with a CTFI of more than 3 months but less than or equal to 6 months, a “promising” number of durable responses was observed.

Anlotinib/Irinotecan Shows Promise, Durable Responses in ES-SCLC

Tim Cortese
August 15th 2025
Article
Navigating the Evolving Second-Line Landscape of Metastatic Urothelial Carcinoma

Navigating the Evolving Second-Line Landscape of Metastatic Urothelial Carcinoma

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
August 15th 2025
Podcast
Geraldine O’Sullivan Coyne, MD, MRCPI, PhD, shares how a new position presents a “good opportunity” to improve community-based clinical trial access.

New Unit Aims to Expand Trial and Therapy Options in The Community Setting

Russ Conroy
August 15th 2025
Article
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 15th 2025
Podcast
Unveiling the Potential of Zenocutuzumab: A Breakthrough in NSCLC and Pancreatic Adenocarcinoma Treatment

Unveiling the Potential of Zenocutuzumab: A Breakthrough in NSCLC and Pancreatic Adenocarcinoma Treatment

Sanan Rasheed, MBBS;Umer Farooq, MBBS;Aiman Waheed, MBBS;Musharaf Khalid Bhutta, MBBS;Adnan Bhat, MD;Hamza Nazir, MBBS;Muhammad Hamza Gul, MBBS, MD;Ayesha Aman, MBBS;Zainab Ibrahim, MBBS;Abdul Baseer Wardak, MBBS
August 15th 2025
Article
The development of non-narcotic pain medication after GI surgery may help relieve chronic pain without the risk of opioid dependence.

Optimizing Stepwise Pain Relief Management in the Perioperative GI Setting

Roman Fabbricatore
August 15th 2025
Article